SCHEMBL6094438

SCHEMBL6094438

CC(C)(C)OC(=O)N1CC2CN(CCc3ccc(C#N)cc3)CC2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.48
KCNJ1 P48048 3/20 0.47
KCNH2 Q12809 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.44
DRD2 P14416 5/20 0.43
DRD3 P35462 5/20 0.43
NR1H2 P55055 1/20 0.42
AR P10275 1/20 0.41
EGLN2 Q96KS0 1/20 0.41
HTR1A P08908 1/20 0.41
DRD4 P21917 1/20 0.41
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
OPRM1 P35372 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16616368 0.88 GPR119 (0.50) GPR119DRD2DRD3NR1H2AR
SCHEMBL6095505 0.85 GPR119 (0.51) GPR119HRH1HRH3
SCHEMBL6094069 0.82 GPR119 (0.43) GPR119NR1H2AREGLN2HRH1
SCHEMBL6093964 0.82 GPR119 (0.43) GPR119DRD2NR1H2AREGLN2
SCHEMBL2967666 0.81 GPR119 (0.44) GPR119KCNJ1KCNH2L3MBTL1DRD2
SCHEMBL20511213 0.80 GPR119 (0.51) GPR119NR1H2AREGLN2HRH3
SCHEMBL22914840 0.80 GPR119 (0.51) GPR119NR1H2AREGLN2HRH3
SCHEMBL6096873 0.78 KCNH2 (0.50) GPR119KCNH2L3MBTL1EGLN2HTR2A
SCHEMBL6095152 0.78 KCNH2 (0.50) GPR119KCNH2L3MBTL1EGLN2HTR2A
SCHEMBL6095202 0.78 USP30 (0.43) GPR119DRD2NR1H2EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144914-B2 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2006-12-05 US disclosed
EP-1360187-B1 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
US-20040053986-A1 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2004-03-18 US disclosed
EP-1360187-A1 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-11-12 EP disclosed
WO-2002060902-A1 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053986-A1 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias KCNH1, KCNH2, CACNA1E GPR119 3060/4885KCNJ1 98/4885KCNH2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.